Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) Short Interest Up 83.4% in December

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 246,800 shares, an increase of 83.4% from the December 15th total of 134,600 shares. Based on an average trading volume of 509,600 shares, the short-interest ratio is currently 0.5 days. Currently, 27.9% of the company’s shares are sold short.

Separately, ValuEngine upgraded Hancock Jaffe Laboratories from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 5th.

HJLI stock opened at $9.00 on Thursday. Hancock Jaffe Laboratories has a one year low of $5.28 and a one year high of $20.25. The company’s 50 day moving average price is $7.88 and its two-hundred day moving average price is $2.26.

Hancock Jaffe Laboratories (NASDAQ:HJLI) last issued its earnings results on Monday, November 16th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). On average, analysts anticipate that Hancock Jaffe Laboratories will post -0.34 EPS for the current year.

About Hancock Jaffe Laboratories

Hancock Jaffe Laboratories, Inc, a medical device company, develops and sells tissue based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries.

Featured Story: How is a buy-side analyst different from a sell-side analyst?